Trials / Completed
CompletedNCT00648999
Safety and Efficacy of Kaletra in ARV Therapy Experienced Patients
Phase IV, Non Randomized Study in ARV Experienced Patients Under Switch Therapy With Kaletra
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 207 (actual)
- Sponsor
- AbbVie (prior sponsor, Abbott) · Industry
- Sex
- All
- Age
- 17 Years
- Healthy volunteers
- Not accepted
Summary
To demonstrate that patients treated with Kaletra have an improvement in their quality of life compared to the quality of life they had with their previous NRTI therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | lopinavir/ritonavir | lopinavir/ritonavir 400 mg/100 mg bid 48 weeks of treatment |
Timeline
- Start date
- 2003-11-01
- Primary completion
- 2006-12-01
- Completion
- 2006-12-01
- First posted
- 2008-04-01
- Last updated
- 2013-03-15
Locations
13 sites across 1 country: Mexico
Source: ClinicalTrials.gov record NCT00648999. Inclusion in this directory is not an endorsement.